Market Research Future (MRFR) has published a cooked research report on the “India Diabetes Market” that contains information from 2024 to 2032. The India Diabetes Market is estimated to register a CAGR of 6.54% during the forecast period of 2024 to 2032.

India Diabetes Market Highlights

India Diabetes Market is accounted to register a CAGR of 6.54% during the forecast period and is estimated to reach USD 11.46 Billion by 2032.

India Diabetes refers to the widespread prevalence and impact of diabetes within the population of India. It is a chronic metabolic disorder characterized by high blood glucose levels resulting from either insufficient insulin production or ineffective utilization of insulin. India has witnessed a significant rise in diabetes cases due to various factors such as sedentary lifestyles, unhealthy diets, genetic predisposition, and urbanization. The country faces a unique challenge with diabetes, as it affects people across different age groups, socio-economic backgrounds, and geographic regions. India Diabetes poses a substantial burden on public health, leading to increased morbidity, mortality, and healthcare costs, emphasizing the need for comprehensive strategies encompassing awareness, prevention, early detection, and management to address this pressing health issue.

Key Players

MRFR recognizes the following companies as the key players in the India Diabetes Market— Novo Nordisk A/S, USV Private Limited, Sanofi-aventis U.S, Novartis AG, Merck & Co Inc, Becton Dickinson and Company, Roche Diabetes Care Inc, Johnson & Johnson Services, Inc, Bayer.

Segment Analysis

The India Diabetes Market has been segmented based on Type, Test, Devices, and Treatment.

Based on Type, the market is segmented into Type 1, Type 2, and Gestational diabetes. The Type 1 category dominates the Diabetes market due to its inherent reliance on insulin therapy for lifelong management.

Based on the Test, the market is segmented into Random blood sugar tests, Fasting blood sugar tests, Oral glucose tolerance tests, Initial glucose challenge tests, and others. The Random blood sugar test category dominates the Diabetes market due to its convenience and ability to provide immediate glucose level assessment without requiring fasting or specific timing.

Based on Devices, the market is segmented into Blood glucose monitoring devices, Diabetes management devices, and others. The Store-Based category dominates the Diabetes market due to its wide availability, personalized assistance, and the convenience of purchasing diabetes-related products and medications in physical retail outlets.

Based on Treatment, the market is segmented into Medications, Insulin therapy, Transplantation, Bariatric surgery, and others. The Medications category dominates the Diabetes market due to its crucial role in managing blood sugar levels and controlling the progression of the disease, offering a wide range of options including oral medications and insulin injections.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of India Diabetes Market Research Report

Regional Analysis

The India Diabetes Market, based on region, has been divided into Western, Eastern, Southern, Northern, and Central Regions.

In the context of the Indian diabetes market, the western region is identified as the largest market for diabetes, while the Eastern and Northern regions are emerging as the second-largest markets. Additionally, the Southern Indian market is anticipated to experience substantial growth during the forecasted period. However, the Central region is expected to have moderate growth with limitations in the market.

Key Findings of the Study

• In the context of the Indian diabetes market, the western region holds the largest market share, while the eastern and northern regions are also witnessing substantial growth and are the second-largest markets for India Diabetes. Additionally, the southern Indian market is expected to experience significant growth during the forecasted period. However, the central region is anticipated to have a moderate growth rate, albeit with certain limitations.


• Based on the Type, the Market has been segmented into Type 1 holding the largest market in 2023.


• Novo Nordisk A/S, USV Private Limited, sanofi-aventis U.S, Novartis AG, Merck & Co Inc, Becton Dickinson and Company, Roche Diabetes Care Inc, Johnson & Johnson Services, Inc, Bayer.